论文部分内容阅读
来自于加拿大渥太华大学的Sarah E.Lawrence 教授及其同事开展的一项最新研究的结果显示,对持续男性乳房发育(gyne-comastia)的少年而言,他莫昔芬(tamoxifen,TX)或雷洛昔芬(raloxifene,RX)可安全有效地抑制乳腺内雌激素受体的活性,减小乳腺的大小。约有10%的青春期乳腺持续发育的男性患者3年内不能自行缓解;研究人员对1995～2000年间在医院治疗过的患者进行了一项回顾性的病历审查。在该项回顾性病历审查中,15例患者平均接受 TX 治疗5.2个月,10例患者平均接受 RX 治疗4.9个月,另13人除了医生对患者的保证外无特殊的治疗;患者基线时的乳腺直径平均分别为4.6cm、3.8cm 和4.7cm。研究发现 TX 治疗可使乳腺直径平均降低2.1cm(45%),
The results of a recent study by Professor Sarah E. Lawrence and colleagues from the University of Ottawa, Canada, show that for juvenile gyne-comastia, tamoxifen (TX) or thunder Raloxifene (raloxifene, RX) can safely and effectively inhibit the activity of estrogen receptors in the breast, reducing the size of the breast. About 10% of male patients with persistent adolescent mammary glands can not relieve themselves within 3 years; the researchers conducted a retrospective review of the medical records of patients treated in the hospital between 1995 and 2000. In this retrospective review of the medical records, 15 patients received an average of 5.2 months of TX treatment, 10 received 4.9 months on average and another 13 received no special treatment other than a physician’s assurance of the patient. Patients at baseline The average diameter of breast was 4.6cm, 3.8cm and 4.7cm respectively. The study found that TX treatment can reduce the mean diameter of breast 2.1cm (45%),